Manganese dioxide-catalase nano-carrier as well as preparation method and application thereof

By preparing a core-shell structured manganese dioxide-catalase nanocarrier, the problem of insufficient GSH consumption capacity of manganese dioxide nanoparticles in tumor cells was solved, realizing the programmed consumption of hydrogen peroxide and reduced glutathione, thereby improving the therapeutic effect and drug delivery capability of tumor treatment.

CN118987238APending Publication Date: 2024-11-22XI AN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411086765.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Manganese dioxide nanoparticles have insufficient GSH consumption capacity in tumor cells, making it difficult for them to sequentially consume hydrogen peroxide and neutralize reduced glutathione, thus affecting their function in the tumor microenvironment.

Method used

A method for preparing manganese dioxide-catalase nanocarriers was adopted, which involves cross-linking with glutaraldehyde and reverse precipitation with acetone solvent to form core-shell structured nanoparticles. The outer shell is catalase, and the inner core is manganese dioxide nanoparticles protected by albumin, thereby achieving programmed consumption of hydrogen peroxide and reduced glutathione.

Benefits of technology

It achieves effective consumption of hydrogen peroxide and reduced glutathione in the tumor microenvironment, improving the efficacy of tumor treatment and enhancing drug delivery capabilities, making it suitable for chemotherapy and photodynamic therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987238A_ABST
    Figure CN118987238A_ABST
Patent Text Reader

Abstract

The invention discloses a manganese dioxide-catalase nano-carrier as well as a preparation method and application thereof, and belongs to the technical field of functional materials. The preparation method of the nano-carrier comprises the following steps: firstly preparing albumin-protected manganese dioxide nano-particles, then preparing aggregated albumin-protected manganese dioxide nano-particles through acetone solvent reverse precipitation and glutaraldehyde crosslinking, and finally wrapping the aggregated albumin-protected manganese dioxide nano-particles with catalase. The manganese dioxide-catalase nano-carrier with the core-shell structure is formed. The carrier has good physical adsorption loading capacity for various small molecule drugs, can be used as a delivery carrier of the small molecule drugs, can sequentially consume hydrogen peroxide and reduced glutathione, can effectively remodel a tumor microenvironment, and improves quality and efficiency for active oxygen dependent tumor treatment means.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of functional materials, and specifically relates to a manganese dioxide-catalase nanocarrier and a preparation method and application thereof. Background Art

[0002] Nano drug carriers help improve the enrichment efficiency of small molecule drugs in tumor sites and increase the half-life of blood circulation, etc. In addition, carriers with active response to the tumor microenvironment can reshape the tumor microenvironment, such as changing hypoxia and reducing the concentration of reduced glutathione in tumor cells, which has a more positive significance for some types of treatment that rely on reactive oxygen to kill tumors (such as photodynamic therapy, sonodynamic therapy, etc.).

[0003] Nanoparticles based on manganese dioxide are a star substance in nanocarrier research in recent years. It can be used as an oxygen-generating agent and is also used to consume glutathione (GSH) in tumor cells. However, in the actual tumor microenvironment, the multi-responsiveness of manganese dioxide causes a certain contradiction in the performance of these two functions, especially affecting its ability to consume GSH in tumor cells. Studies have shown that H2O2 outside tumor cells can react efficiently with manganese dioxide in a slightly acidic environment. However, a fact that contradicts this is that high concentrations of GSH are mainly distributed inside tumor cells. It can be predicted that manganese dioxide nanoparticles can be consumed and degraded by H2O2 in large quantities before being delivered to tumor cells. Therefore, the ability of manganese dioxide nanoparticles to regulate GSH in tumor cells still needs to be improved. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings of the above-mentioned prior art and provide a manganese dioxide-catalase nanocarrier and its preparation method and application to solve the problem that manganese dioxide is difficult to sequentially consume hydrogen peroxide to produce oxygen and neutralize reduced glutathione.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] A method for preparing a manganese dioxide-catalase nanocarrier comprises the following steps:

[0007] Step 1, adding a manganese chloride solution dropwise to an albumin solution to obtain a mixed solution, adjusting the pH value of the mixed solution to 12, and stirring the mixture to obtain an albumin-protected manganese dioxide nanoparticle solution, which is a MnO2-Pro solution;

[0008] Step 2, adding acetone to the MnO2-Pro solution, obtaining a mixture after reaction, adding glutaraldehyde to the mixture, mixing, obtaining self-polymerized cross-linked albumin-protected manganese dioxide nanoparticles after centrifugation and purification, and mixing the self-polymerized cross-linked albumin-protected manganese dioxide nanoparticles with a phosphate buffer solution to obtain an MP solution;

[0009] Step 3, adding phosphate buffer, catalase solution, acetone and glutaraldehyde solution to the MP solution in sequence, stirring and centrifuging to obtain manganese dioxide-catalase nanocarriers.

[0010] A further improvement of the present invention is:

[0011] Preferably, in step 1, the concentration of the manganese chloride solution is 5 to 20 mg / mL; the concentration of the albumin solution is 2 to 20 mg / mL.

[0012] Preferably, in step 1, the mixing ratio of the manganese chloride solution and the albumin solution is 1:9.

[0013] Preferably, in step 2, the volume ratio of acetone to MnO2-Pro solution is (2-5):1.

[0014] Preferably, in step 2, the volume ratio of the MnO2-Pro solution to glutaraldehyde is 50:1.

[0015] Preferably, in step 3, the solute of the hydrogen peroxide lysing enzyme solution is catalase, the solvent is phosphate buffer solution, and the concentration is 5 to 25 mg / mL.

[0016] Preferably, in step 3, the volume ratio of MP solution, phosphate buffer, catalase solution, and glutaraldehyde is 500:1000:(500-1000):3;

[0017] In step 3, the mixing volume ratio of acetone and MP solution is (1.5-3):1.

[0018] A manganese dioxide-catalase nanocarrier prepared by any one of the above preparation methods, wherein the manganese dioxide-catalase nanocarrier is a core-shell structure, comprising an outer shell and an inner core, wherein the outer shell is composed of glutaraldehyde-crosslinked catalase; and the inner core is composed of glutaraldehyde-crosslinked albumin-protected manganese dioxide nanoparticles.

[0019] An application of the above-mentioned manganese dioxide-catalase nanocarrier is used for loading drugs.

[0020] An application of the above-mentioned manganese dioxide-catalase nanocarrier is used to consume hydrogen peroxide and reduced glutathione in sequence in the tumor microenvironment.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The invention discloses a method for preparing a manganese dioxide-catalase nanocarrier, and the specific preparation steps include: 1) preparing albumin-protected manganese dioxide nanoparticles; 2) preparing aggregated manganese dioxide nanoparticles by reverse precipitation of acetone solvent and cross-linking with glutaraldehyde; 3) introducing an appropriate amount of catalase. During the whole reaction process, the manganese dioxide-catalase nanocarrier is prepared by reverse precipitation of acetone solvent and cross-linking with glutaraldehyde. The invention prepares manganese dioxide-albumin-fused nanoparticles (MP) by reverse solvent precipitation, further uses reverse solvent precipitation, and fixes with a cross-linking agent, so that catalase can be coated on the surface of MP to prepare MP@CAT.

[0023] The present invention also discloses a manganese dioxide-catalase nanocarrier, which is a core-shell structure, the outermost shell of the core-shell structure is catalase, and the catalase is used as a shell, and multiple particles are wrapped inside, and the particles inside react with each other to form multiple particles in an aggregated state. The structure allows the catalase to serve as the first layer of protection, and during the movement of the entire particle, the catalase first reacts with hydrogen peroxide to protect the manganese dioxide nanoparticles. The albumins react with each other through the hydroxyl groups and carboxyl groups on the surface to form relatively large aggregated particles, which are bonded to each other. Because the particles are uneven, there are gaps between the particles, and these gaps can serve as good drug carriers. The structure can carry more drugs.

[0024] The present invention also discloses an application of a manganese dioxide-catalase nanocarrier, which relies on physical adsorption to load small molecule drugs in different forms, has good physical adsorption loading capacity for a variety of small molecule drugs, and can be used as a delivery carrier for small molecule drugs. Therefore, the manganese dioxide-hydrogen peroxide nanocarrier is expected to be assembled with matching drug small molecules into nanomedicines with tumor microenvironment regulation to improve the therapeutic effect of tumors. This substance can be used for drug delivery and can effectively reshape the tumor microenvironment, improving the quality and efficiency of tumor treatment methods that rely on reactive oxygen. It provides a convenient drug carrier for chemotherapy and photodynamic therapy of tumors.

[0025] The present invention also discloses an application of a manganese dioxide-catalase nanocarrier. The manganese dioxide-catalase nanocarrier is tested by sequentially introducing hydrogen peroxide and reduced glutathione to prove that the manganese dioxide-catalase nanocarrier has the ability to consume hydrogen peroxide and reduced glutathione in a programmed manner, and can meet the regulation of high-concentration hydrogen peroxide and high-concentration reduced glutathione in the tumor microenvironment. Before the manganese dioxide-catalase nanocarrier is delivered into tumor cells, the catalase on the surface first reacts with hydrogen peroxide and is consumed. After being transported into the tumor, the GSH inside the tumor passes through albumin and reacts with the manganese dioxide nanoparticles, and the manganese dioxide consumes the GSH. In addition, by simulating the general process of interaction between nanoparticles and tumor tissue in a solution, it is proved that the MP@CAT prepared by the present invention can resist the erosion of hydrogen peroxide. After acting with hydrogen peroxide for 30 minutes, the retention amount of manganese dioxide is still about 80%; at the same time, when it comes into contact with reduced glutathione, it can still quickly neutralize it, thereby theoretically achieving the purpose of sequentially consuming hydrogen peroxide and reduced glutathione. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 A schematic diagram of the process of the present invention;

[0027] Figure 2 This is a particle size distribution diagram of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 1 of the present invention;

[0028] Figure 3 TEM image of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 1 of the present invention;

[0029] Figure 4 This is a real photo of the manganese dioxide-hydrogen peroxide nanocarrier (MH@CAT) obtained in Example 1 of the present invention after loading various small molecule drugs;

[0030] Figure 5 The loading capacity of the manganese dioxide-hydrogen peroxide nanocarrier (MH@CAT) obtained in Example 1 of the present invention for various small molecule drugs is calculated;

[0031] Figure 6 The oxygen production capacity of the manganese dioxide-hydrogen peroxide nanocarrier (MH@CAT) obtained in Example 1 of the present invention in hydrogen peroxide;

[0032] Figure 7 Schematic diagram of the programmed consumption of hydrogen peroxide and reduced glutathione by the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Examples 1 to 3 of the present invention;

[0033] Figure 8The performance characterization of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 1 of the present invention in programmed consumption of hydrogen peroxide and reduced glutathione;

[0034] Fig. 9 The performance characterization of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 2 of the present invention in programmed consumption of hydrogen peroxide and reduced glutathione;

[0035] Fig.10 The performance characterization of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 3 of the present invention in programmed consumption of hydrogen peroxide and reduced glutathione;

[0036] Fig.11 Characterization of the oxygen production capacity of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 1 of the present invention in human breast cancer cells MDA-MB-231;

[0037] Fig.12 The present invention is to characterize the ability of manganese dioxide nanoparticles (MH) and manganese dioxide-catalase nanocarriers (MH@CAT) obtained in Example 1 of the present invention to consume reduced glutathione in human breast cancer cells MDA-MB-231;

[0038] Fig.13 The cell killing ability of the manganese dioxide-hydrogen peroxide nanocarrier loaded with dihydrochlorin e6 (MH@CAT-Ce6) obtained in Example 1 of the present invention on human breast cancer cells MDA-MB-231. DETAILED DESCRIPTION

[0039] The present invention is further described in detail below in conjunction with the accompanying drawings:

[0040] The first aspect of the present invention discloses a method for preparing a manganese dioxide-catalase nanocarrier, comprising the following steps:

[0041] Step 1, preparation of albumin-protected manganese dioxide nanoparticles (MnO2-Pro);

[0042] The albumin solution with a concentration of 2 to 20 mg / mL is prepared by dissolving the albumin in deionized water; the manganese chloride solution with a concentration of 5 to 20 mg / mL is prepared by dissolving the manganese chloride in deionized water; the manganese chloride solution is added dropwise to the albumin solution; the sodium hydroxide solution with a concentration of 0.5 to 3 M is added dropwise to the mixed solution, the pH value is adjusted to 12, and the reaction is stirred at room temperature overnight to obtain an albumin-protected manganese dioxide nanoparticle MnO2-Pro solution, which is a MnO2-Pro solution.

[0043] Preferably, the volume ratio of the manganese chloride solution to the albumin solution is 1:9.

[0044] Preferably, the albumin is bovine serum albumin, human serum albumin or the like.

[0045] Step 2, preparing self-polymerized and cross-linked manganese dioxide nanoparticles (MP).

[0046] Acetone was added dropwise to MnO2-Pro, mixed and reacted for 5 to 20 minutes to allow the albumin to precipitate; 40 to 70% glutaraldehyde solution was added dropwise to the mixture, mixed and reacted for 1 hour; nanoparticles in the mixture were purified by centrifugation to obtain self-polymerized cross-linked albumin-protected manganese dioxide nanoparticles (MP), which were diluted with phosphate buffer solution (pH 8.5) to the original volume of MnO2-Pro to obtain MP solution.

[0047] Preferably, the volume ratio of the MnO2-Pro solution to glutaraldehyde is 50:1.

[0048] Preferably, the amount of acetone added is 2 to 5 times the volume of the MnO2-Pro solution.

[0049] Step 3: Preparation of manganese dioxide-catalase nanocarriers (MP@CAT)

[0050] First, a phosphate buffer solution (pH 8.5) was used to prepare a catalase solution with a concentration of 5 to 25 mg / mL. Subsequently, a phosphate buffer solution (pH 8.5), a catalase solution, acetone, and a glutaraldehyde solution (concentration of 40 to 70%) were added dropwise to the MP solution in the following order, and the reaction was stirred for 1 hour; the nanoparticles in the mixture were purified by centrifugation to obtain a manganese dioxide-catalase nanocarrier (MP@CAT), which was diluted to the original MP volume for storage as an MP@CAT solution.

[0051] In the above process, catalase is the raw material for preparing the final product, and then acetone is added to precipitate the protein substances, and then glutaraldehyde is added to cross-link the protein substances, so that the polymerized albumin-protected manganese dioxide nanoparticles are wrapped by catalase to form Figure 1 MP@CAT in.

[0052] The volume ratio of the MP solution, phosphate buffer, catalase solution and glutaraldehyde is 500:1000:(500-1000):3.

[0053] The amount of acetone added is 1.5 to 3 times the volume of the MP solution.

[0054] The second aspect of the present invention discloses a manganese dioxide-catalase nanocarrier obtained by the above preparation method, comprising an outer shell and an inner core, wherein the outer shell is composed of glutaraldehyde-crosslinked catalase; and the inner core is composed of glutaraldehyde-crosslinked albumin-protected manganese dioxide nanoparticles.

[0055] The third aspect of the present invention discloses that the manganese dioxide-catalase nanocarrier can be used to load different types of drugs. The process of loading the drug on MP@CAT comprises the following steps:

[0056] First, the small molecule drug was dissolved in pure water to prepare a drug molecule solution with a concentration of 0.4-3 mg / mL; then, the drug molecule solution was mixed evenly with the MP solution (albumin concentration was 0.5 mg / mL) and stirred overnight; finally, the nanoparticles loaded with the small molecule drug in the mixture were obtained by centrifugal purification. The drug loading rate of the above nanoparticles was tested.

[0057] In this step, the small molecule drug is a commonly used chemotherapy drug and photosensitizer such as Cisplatin (Cis-Pt), Methylene Blue (MB), Chlorin e6 (Ce6), Rose Bengal (RB) or Doxorubicin (DOX).

[0058] Preferably, the volume ratio of the drug molecule solution to the MP solution is 1:3.

[0059] The fourth aspect of the present invention discloses an application of a manganese dioxide-catalase nanocarrier to generate oxygen. MP@CAT can generate oxygen in the presence of hydrogen peroxide. The test of the oxygen production capacity of MP@CAT includes the following steps:

[0060] MP@CAT with different concentrations was mixed with hydrogen peroxide and incubated for 10 minutes. A portable dissolved oxygen meter was used to test the oxygen generation every 30 seconds.

[0061] Based on the above-mentioned oxygen-generating applications, a manganese dioxide-catalase nanocarrier was used to programmedly consume hydrogen peroxide or reduced glutathione in the tumor microenvironment.

[0062] MP@CAT can generate oxygen in the presence of hydrogen peroxide without excessive consumption of MnO2, thus ensuring that it can better neutralize GSH when it comes into contact with GSH later, thereby meeting the requirements of simultaneously alleviating hypoxia in the tumor microenvironment and downregulating GSH levels. The test of MP@CAT's programmed consumption of hydrogen peroxide and GSH includes the following steps:

[0063] Step 1: Comparison of the ability of MP and MP@CAT to consume hydrogen peroxide

[0064] Manganese dioxide nanoparticles (MP) and manganese dioxide-catalase nanocarriers (MP@CAT) were added to phosphate buffer solution (pH 7.4), followed by addition of hydrogen peroxide to the two mixed solutions, followed by incubation for 30 minutes, and the ultraviolet absorbance at the maximum absorption wavelength of 370 nm was measured every 5 minutes using a microplate reader.

[0065] Step 2: Comparison of the ability of MP and MP@CAT to consume reduced glutathione

[0066] After incubation for 30 minutes in step 1, different concentrations of reduced glutathione were added to the reaction solution, and the incubation was continued for 30 minutes. The ultraviolet absorbance value at the maximum absorption wavelength of 370 nm was detected by an ELISA instrument every 5 minutes.

[0067] Preferably, the final concentration of hydrogen peroxide in step 1 is 50 μM.

[0068] Preferably, the final concentration of reduced glutathione in step 2 is 10 μM or 5 mM.

[0069] Based on the above-mentioned application of oxygen generation, a manganese dioxide-catalase nanocarrier produces oxygen and consumes reduced glutathione in human breast cancer cells MDA-MB-231 and is used to kill tumor cells.

[0070] Step 1: RDPP is a fluorescent probe that quenches fluorescence when combined with oxygen. Therefore, RDPP was used to detect the amount of oxygen produced in human breast cancer cells MDA-MB-231 in different culture environments. The fluorescence images of the cells were monitored and captured using confocal fluorescence imaging technology.

[0071] Step 2: The relative content of GSH in human breast cancer MDA-MB-231 cells after co-incubation with MP@CAT was tested, and the ability of MP@CAT to deplete reduced glutathione was evaluated compared with the untreated control group.

[0072] Step 3: The manganese dioxide-catalase nanocarrier can be loaded with a photosensitizer, chlorin e6 (Ce6), and used to kill tumor cells through photodynamic therapy.

[0073] MP@CAT was loaded with photosensitizer Ce6 as nanomedicine and co-incubated with human breast cancer cells MDA-MB-231. The power density was 20 mW·cm -2The human breast cancer cells MDA-MB-231 were irradiated with 650nm laser. The MTT method was used to detect the cell killing ability of MP@CAT loaded with Ce6 (MP@CAT-Ce6) on human breast cancer cells MDA-MB-231.

[0074] Preferably, the administration concentration of Ce6 is 1 μM.

[0075] The following is further described in conjunction with specific embodiments:

[0076] Example 1: Preparation of manganese dioxide-catalase nanocarrier capable of programmable consumption of hydrogen peroxide and reduced glutathione, comprising the following steps, as shown in the flow chart: Figure 1 shown.

[0077] Step 1: Preparation of human serum albumin (HSA) protected manganese dioxide nanoparticles (MnO2-HSA).

[0078] HSA was dissolved in deionized water to prepare an albumin solution with a concentration of 11.1 mg / mL; manganese chloride was dissolved in deionized water to prepare a manganese chloride solution with a concentration of 10 mg / mL; 0.2 mL of the manganese chloride solution was added dropwise to 1.8 mL of the albumin solution; 40 μL of 1 M sodium hydroxide solution was added dropwise to the above mixed solution, and the reaction was stirred at room temperature overnight to obtain a human serum albumin-protected manganese dioxide nanoparticle (MnO2-HSA) solution.

[0079] Step 2: Preparation of human serum albumin self-polymerized and cross-linked manganese dioxide nanoparticles (MH).

[0080] 7 mL of acetone was added dropwise to 2 mL of MnO2-HSA, mixed, and reacted for 15 minutes; 40 μL of 50% glutaraldehyde was added dropwise to the above mixture, mixed, and reacted for 1 hour; the nanoparticles in the mixture were purified by centrifugation to obtain human serum albumin self-polymerized cross-linked manganese dioxide nanoparticles (MH), which were diluted to 2 mL with phosphate buffer (pH 8.5) for storage. In this example, human serum albumin was used, so it was abbreviated as MH, which is the MP mentioned above.

[0081] Step 3: Preparation of manganese dioxide-catalase nanocarriers (MH@CAT)

[0082] To 0.5 mL of MH solution, 1 mL of phosphate buffer (pH 8.5), 0.6 mL of catalase solution (20 mg / mL), 1 mL of acetone, and 3 μL of glutaraldehyde solution (50%) were sequentially added and stirred for 1 hour. The nanoparticles in the mixture were purified by centrifugation to obtain manganese dioxide-catalase nanocarriers (MH@CAT), which were diluted to 0.5 mL for storage.

[0083] Example 2: Preparation of manganese dioxide-catalase nanocarriers capable of programmable consumption of hydrogen peroxide and reduced glutathione

[0084] Step 1 and step 2 are the same as in Example 1.

[0085] Step 3: Preparation of manganese dioxide-catalase nanocarriers (MH@CAT)

[0086] To 0.5 mL of MH solution, 1 mL of phosphate buffer (pH 8.5), 0.5 mL of catalase solution, 1 mL of acetone, and 3 μL of glutaraldehyde solution (50%) were sequentially added and stirred for 1 hour. The nanoparticles in the mixture were purified by centrifugation to obtain manganese dioxide-catalase nanocarriers (MH@CAT), which were diluted to 0.5 mL for storage.

[0087] Example 3: Preparation of manganese dioxide-catalase nanocarriers capable of programmable consumption of hydrogen peroxide and reduced glutathione

[0088] Step 1 and step 2 are the same as in Example 1.

[0089] Step 3: Preparation of manganese dioxide-catalase nanocarriers (MH@CAT)

[0090] To 0.5 mL of MH solution, 1 mL of phosphate buffer (pH 8.5), 1 mL of catalase solution (20 mg / mL), 1 mL of acetone, and 3 μL of glutaraldehyde solution (50%) were sequentially added and stirred for 1 hour. The nanoparticles in the mixture were purified by centrifugation to obtain manganese dioxide-catalase nanocarriers (MH@CAT), which were diluted to 0.5 mL for storage.

[0091] Example 4: Testing the hydrodynamic size and transmission electron microscopy morphology of MH@CAT

[0092] The hydrodynamic size of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 1 was characterized by a dynamic light scattering particle size analyzer (DLS). Figure 2 As shown in FIG. 1 , the hydrated particle size of MH@CAT is about 120 nm. The morphology of the manganese dioxide-catalase nanocarrier (MH@CAT) obtained in Example 1 was characterized by transmission electron microscopy. Figure 3 shown.

[0093] Example 5: Evaluation of drug loading performance of MH@CAT. After being mixed with cisplatin (Cis-Pt), methylene blue (MB), chlorin e6 (Ce6), rose bengal (RB) and doxorubicin (DOX), the obtained MH@CAT-Drug loaded with drug molecules was centrifuged and washed. The corresponding photos are shown in Figure 5. Figure 4 As shown. Compared with MH@CAT, the nanoparticles loaded with drug molecules all show the color of the original drug molecules (cisplatin molecules are colorless, so there is no obvious color difference between MH@CAT-CisPt and MH@CAT). Quantitative results show that the encapsulation efficiency of MH@CAT for Cis-Pt, Ce6, DOX, MB and RB is 47.6±2.6%, 47.0±2.3%, 98.0±3.1%, 97.9±2.2% and 89.8±2.3%, respectively. The results are shown in Figure 5 Therefore, MH@CAT can directly load a variety of dye molecules through physical adsorption, and the loading efficiency is high.

[0094] Example 6: Testing the oxygen production capacity of MH@CAT

[0095] Different concentrations of MH@CAT were added to 1mM hydrogen peroxide to make the final concentration of MH@CAT 50-400μg / mL and incubated for 10 minutes. The amount of oxygen generated was tested every 30 seconds using a portable dissolved oxygen meter. The results are shown in Figure 2. Figure 6 As time goes by, different concentrations of MH@CAT can produce oxygen, and the oxygen production capacity is positively correlated with the concentration of MH@CAT.

[0096] Example 7: Testing the ability of MH@CAT to consume hydrogen peroxide and reduced glutathione

[0097] The manganese dioxide nanoparticles (MH) and manganese dioxide-catalase nanocarriers (MH@CAT) obtained in Example 1 were tested, including the following steps, as shown in the flow chart: Figure 7 shown.

[0098] Step 1: Comparison of the ability of MH and MH@CAT to consume hydrogen peroxide

[0099] 20 μL of manganese dioxide nanoparticles (MH) and manganese dioxide-catalase nanocarriers (MH@CAT) were added to 175 μL of phosphate buffer solution (pH 7.4). 2 μL of hydrogen peroxide (5 mM) was added to the above two mixed solutions to make the final concentration of hydrogen peroxide in the reaction system 50 μM, and incubated for 30 minutes.

[0100] Step 2: Comparison of the ability of MH and MH@CAT to consume reduced glutathione

[0101] After incubation for 30 minutes in step 1, 2 μL of reduced glutathione at a concentration of 1 mM or 500 mM was added to the reaction solution, respectively, so that the final concentration of reduced glutathione in the reaction system was 10 μM or 5 mM, respectively, and the incubation was continued for 30 minutes.

[0102] During the incubation process in step 1 and step 2, the ultraviolet absorbance value at the maximum absorption wavelength of 370nm was detected by using an ELISA instrument every 5 minutes. The results are as follows: Figure 8 As shown. Under the condition of high concentration of hydrogen peroxide (50μM), manganese dioxide (MnO2) in MH is continuously degraded to consume hydrogen peroxide; for MH@CAT protected by catalase (CAT), CAT preferentially catalyzes the reaction with hydrogen peroxide, and the MnO2 content contained in it is retained at about 70% to 80%. After 30 minutes, when high concentration of reduced glutathione (5mM) is further introduced into the reaction system, MH is further degraded, and the remaining MnO2 in MH@CAT gradually reacts with reduced glutathione, showing a trend of gradual degradation. Under the condition of low concentration of reduced glutathione (10μM), MnO2 in MH@CAT can still be maintained at a high level without being degraded. Through simulation tests of sequentially introducing hydrogen peroxide and reduced glutathione, it was demonstrated that the manganese dioxide-catalase nanocarrier (MH@CAT) has the ability to programmatically consume hydrogen peroxide and reduced glutathione, which can meet the regulation of high concentrations of hydrogen peroxide (50μM) and high concentrations of reduced glutathione (5mM) in the tumor microenvironment.

[0103] Example 8: Testing the ability of MH@CAT to consume hydrogen peroxide and reduced glutathione

[0104] The manganese dioxide nanoparticles (MH) and manganese dioxide-catalase nanocarriers (MH@CAT) obtained in Example 2 were tested, and steps 1 and 2 were the same as those in Example 3.

[0105] The results are as follows Fig. 9As shown. Under the condition of high concentration of hydrogen peroxide (50μM), manganese dioxide (MnO2) in MH is continuously degraded to consume hydrogen peroxide; for MH@CAT protected by catalase (CAT), CAT preferentially catalyzes the reaction with hydrogen peroxide, and the MnO2 content contained in it is retained at about 60% to 70%. After 30 minutes, when high concentration of reduced glutathione (5mM) is further introduced into the reaction system, MH is further degraded, and the remaining MnO2 in MH@CAT gradually reacts with reduced glutathione, showing a trend of gradual degradation. Under the condition of low concentration of reduced glutathione (10μM), MnO2 in MH@CAT can still be maintained at a high level without being degraded. Through simulation tests of sequentially introducing hydrogen peroxide and reduced glutathione, it was demonstrated that the manganese dioxide-catalase nanocarrier (MH@CAT) has the ability to programmatically consume hydrogen peroxide and reduced glutathione, which can meet the regulation of high concentrations of hydrogen peroxide (50μM) and high concentrations of reduced glutathione (5mM) in the tumor microenvironment.

[0106] Example 9: Testing the ability of MH@CAT to consume hydrogen peroxide and reduced glutathione

[0107] The manganese dioxide nanoparticles (MH) and manganese dioxide-catalase nanocarriers (MH@CAT) obtained in Example 3 were tested, and steps 1 and 2 were the same as in Example 3.

[0108] The results are as follows Fig.10 As shown. Under the condition of high concentration of hydrogen peroxide (50μM), manganese dioxide (MnO2) in MH is continuously degraded to consume hydrogen peroxide; for MH@CAT protected by catalase (CAT), CAT preferentially catalyzes the reaction with hydrogen peroxide, and the MnO2 content contained therein is retained by about 90%. After 30 minutes, when high concentration of reduced glutathione (5mM) is further introduced into the reaction system, MH is further degraded, and MnO2 in MH@CAT is still protected by excess CAT and hardly reacts with reduced glutathione to degrade. Under the condition of low concentration of reduced glutathione (10μM), MnO2 in MH@CAT can still be maintained at a high level without being degraded. Through simulation tests of sequentially introducing hydrogen peroxide and reduced glutathione, it was demonstrated that the manganese dioxide-catalase nanocarrier (MH@CAT) has the ability to programmatically consume hydrogen peroxide and reduced glutathione, which can meet the regulation of high concentrations of hydrogen peroxide (50μM) and high concentrations of reduced glutathione (5mM) in the tumor microenvironment.

[0109] Example 10: Oxygen production capacity and reduced glutathione consumption capacity of MH@CAT in human breast cancer cells MDA-MB-231

[0110] Step 1: Testing the oxygen production capacity of MH@CAT in human breast cancer cells MDA-MB-231

[0111] RDPP (a fluorescent probe that quenches fluorescence when combined with oxygen) was used to detect the oxygen content of cells in different culture environments. 4 Human breast cancer cells MDA-MB-231 were inoculated at a density of 1 / well. After 24 hours, 50 μM hydrogen peroxide and 4 μM RDPP probe were added, incubated for 4 hours, and washed with PBS. Then 100 μg / mL MH@CAT was added to the cell culture dish and incubated for another 4 hours. Confocal fluorescence imaging technology was used to monitor and capture the fluorescence images of the cells. The results are shown in Figure 2. Fig.11 shown.

[0112] When human breast cancer cells MDA-MB-231 were co-incubated in an environment containing both MH@CAT and hydrogen peroxide, the RDPP fluorescence was significantly quenched, indicating that a certain amount of oxygen was produced in the cells, thus proving that MH@CAT has a certain oxygen-producing capacity in human breast cancer cells MDA-MB-231.

[0113] Step 2: Testing the ability of MH@CAT to deplete reduced glutathione in human breast cancer cells MDA-MB-231

[0114] The ability of MH@CAT to consume reduced glutathione was evaluated by detecting the relative content of GSH in human breast cancer cells MDA-MB-231 after co-incubation with MH and MH@CAT, and compared with the untreated control group. Human breast cancer cells MDA-MB-231 were seeded in a cell culture dish and hydrogen peroxide (final concentration of 50 μM) was added and incubated for 4 hours. The culture medium was then discarded and replaced with fresh culture medium containing 100 μg / mL MH or MH@CAT. After another 4 hours of incubation, glutathione levels were detected using a glutathione detection kit, and the results are shown in Figure 2. Fig.12 As shown. Compared with the untreated control group, MH and MH@CAT reduced the GSH level to about 85% and 75% of the original, respectively. Although the mean values ​​of the two were not much different, there was a significant difference between them. Finally, it was shown that both MH and MH@CAT could significantly reduce the content of GSH in human breast cancer cells MDA-MB-231.

[0115] Example 11: Cytotoxicity of MH@CAT loaded with dihydrochlorin e6 against human breast cancer cells MDA-MB-231

[0116] The MTT method was used to detect the cell killing ability of MH@CAT loaded with dihydrochlorin e6 (MH@CAT-Ce6) on human breast cancer cells MDA-MB-231. The power density was 20 mW·cm -2 The results were as follows: Fig.13 As shown, in the presence of 50 μM hydrogen peroxide, when the Ce6 concentration reached 1 μM, the cell killing ability of MH@CAT-Ce6 on human breast cancer cells MDA-MB-231 was as high as about 90%, indicating that MH@CAT loaded with dihydrochlorin e6 combined with laser irradiation has a strong killing effect on human breast cancer cells MDA-MB-231.

[0117] Example 12

[0118] In this embodiment, in step 1, the concentration of the manganese chloride solution is 5 mg / mL, the concentration of the albumin solution is 2 mg / mL, and the remaining parts not involved are the same as those in Example 1.

[0119] Embodiment 13

[0120] In this embodiment, in step 1, the concentration of the manganese chloride solution is 20 mg / mL, the concentration of the albumin solution is 20 mg / mL, and the remaining parts not involved are the same as those in Example 1.

[0121] Embodiment 14

[0122] In this embodiment, in step 1, the concentration of the manganese chloride solution is 10 mg / mL, the concentration of the albumin solution is 15 mg / mL, and the remaining parts not involved are the same as those in Example 1.

[0123] Embodiment 15

[0124] In this embodiment, in step 2, the amount of acetone added is 4 mL, and the remaining parts not involved are the same as those in embodiment 1.

[0125] Example 16

[0126] In this embodiment, in step 2, the amount of acetone added is 10 mL, and the remaining parts not involved are the same as those in Example 1.

[0127] Embodiment 17

[0128] In this embodiment, in step 3, the concentration of the catalase solution is 5 mg / mL, and the remaining parts not involved are the same as those in Example 1.

[0129] Embodiment 18

[0130] In this embodiment, in step 3, the concentration of the catalase solution is 25 mg / mL, and the remaining parts not involved are the same as those in Example 1.

[0131] Embodiment 19

[0132] In this embodiment, in step 3, the amount of acetone solution added is 0.75 mL, and the remaining parts not involved are the same as those in embodiment 1.

[0133] Embodiment 20

[0134] In this embodiment, in step 3, the amount of acetone solution added is 1.5 mL, and the remaining parts not involved are the same as those in embodiment 1.

[0135] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a manganese dioxide-catalase nanocarrier, characterized in that: The following steps are involved: Step 1, adding a manganese chloride solution dropwise to an albumin solution to obtain a mixed solution, adjusting the pH value of the mixed solution to 12, and stirring the mixture to obtain an albumin-protected manganese dioxide nanoparticle solution, which is a MnO2-Pro solution; Step 2, adding acetone to the MnO2-Pro solution, obtaining a mixture after reaction, adding glutaraldehyde to the mixture, mixing, obtaining self-polymerized cross-linked albumin-protected manganese dioxide nanoparticles after centrifugation and purification, and mixing the self-polymerized cross-linked albumin-protected manganese dioxide nanoparticles with a phosphate buffer solution to obtain an MP solution; Step 3, adding phosphate buffer, catalase solution, acetone and glutaraldehyde solution to the MP solution in sequence, stirring and centrifuging to obtain manganese dioxide-catalase nanocarriers.

2. The method for preparing a manganese dioxide-catalase nanocarrier according to claim 1, characterized in that: In step 1, the concentration of the manganese chloride solution is 5 to 20 mg / mL; the concentration of the albumin solution is 2 to 20 mg / mL.

3. The method for preparing a manganese dioxide-catalase nanocarrier according to claim 1, characterized in that: In step 1, the mixing ratio of the manganese chloride solution and the albumin solution is 1:

9.

4. The method for preparing a manganese dioxide-catalase nanocarrier according to claim 1, characterized in that: In step 2, the volume ratio of acetone to MnO2-Pro solution is (2-5):

1.

5. The method for preparing a manganese dioxide-catalase nanocarrier according to claim 1, characterized in that: In step 2, the volume ratio of MnO2-Pro solution to glutaraldehyde is 50:

1.

6. The method for preparing a manganese dioxide-catalase nanocarrier according to claim 1, characterized in that: In step 3, the solute of the hydrogen peroxide lysing solution is catalase, the solvent is phosphate buffer solution, and the concentration is 5 to 25 mg / mL.

7. The method for preparing a manganese dioxide-catalase nanocarrier according to claim 1, characterized in that: In step 3, the volume ratio of MP solution, phosphate buffer, catalase solution, and glutaraldehyde is 500:1000:(500-1000):3; In step 3, the mixing volume ratio of acetone and MP solution is (1.5-3):

1.

8. A manganese dioxide-catalase nanocarrier prepared by the preparation method according to any one of claims 1 to 7, characterized in that: The manganese dioxide-catalase nanocarrier is a core-shell structure, comprising an outer shell and an inner core, wherein the outer shell is composed of glutaraldehyde-crosslinked catalase; and the inner core is composed of glutaraldehyde-crosslinked albumin-protected manganese dioxide nanoparticles.

9. An application of the manganese dioxide-catalase nanocarrier according to claim 8, characterized in that: Used to load medicine.

10. A use of the manganese dioxide-catalase nanocarrier according to claim 8, characterized in that: Used to sequentially deplete hydrogen peroxide and reduced glutathione in the tumor microenvironment.